Monogram Orthopaedics commenced trading on NASDAQ under the ticker symbol MGRM.

The company grew its orthopedic business 9% in 1Q23, driven by favorable order timing and contributions from new products.

The company grew over 45% in 1Q23 as it further penetrates the large, underserved bunion surgical procedure market.

The company grew 26% in 1Q23 against strong comps than most of the orthopedic industry, but opted to not increase it revenue guidance.

The company grew 11.1% on a pro forma basis in 1Q23, driven by strength across its businesses and no major dissyngeries from the merge

The company grew more than 30% in the first quarter of 2023 despite ongoing staffing challenges at pediatric hospitals.

The company grew 20% in 1Q23 due to improving procedure volumes, competitive rep recruiting and robotic pull-through.

The company’s 1Q23 sales declined in the high teens as its business model shift and operational challenges take a toll.

The company grew in the high teens in 1Q23 due to easing market pressures in the U.S. and some international markets in “overdrive.”

The company grew 54% in 1Q23 and acquired the REMI navigated robotics system as ATEC prepares for the modernization of spine surgery.